Ligand Pharmaceuticals (LGND) Curent Deferred Tax Liability (2012 - 2015)

Ligand Pharmaceuticals has disclosed Curent Deferred Tax Liability across 4 years of filings, most recently posting $258000.0 for Q1 2015.

• Curent Deferred Tax Liability for Q1 2015 came in at $258000.0, down 83.61% year-over-year; the trailing twelve-month figure through Mar 2015 was $258000.0 (down 83.61% YoY), and the FY2014 annual result was $257000.0, down 83.67% from the prior year.
• Curent Deferred Tax Liability came in at $258000.0 for Q1 2015 at Ligand Pharmaceuticals, roughly flat from $257000.0 in the prior quarter.
• In the past five years, Curent Deferred Tax Liability ranged from a high of $1.6 million in Q4 2012 to a low of $257000.0 in Q4 2014.
• The 4-year median for Curent Deferred Tax Liability is $1.6 million (2013), against an average of $1.3 million.
• Across the five-year window, Curent Deferred Tax Liability retreated 0.44% in 2013 and plunged 83.67% in 2014, its largest moves.
• Ligand Pharmaceuticals' Curent Deferred Tax Liability stood at $1.6 million in 2012, then declined by 0.44% to $1.6 million in 2013, then slumped by 83.67% to $257000.0 in 2014, then gained by 0.39% to $258000.0 in 2015.
• The last three Curent Deferred Tax Liability figures came in at $258000.0 (Q1 2015), $257000.0 (Q4 2014), and $1.6 million (Q3 2014), per Business Quant data.